News | May 02, 2014

Analogic to offer D&K's BioJet Fusion system with Flex Focus ultrasound for precise, targeted prostate biopsies

Analogic Corp. BK Flex Focus D&K Technologies BioJet Solution Prostate Biopsy

May 2, 2014 — Analogic Corp. has entered into a distribution agreement with D&K Technologies, developer of the BioJet Solution, a revolutionary 3-D magnetic resonance imagining (MRI) transrectal ultrasound (TRUS) fusion technology. Analogic will distribute the BioJet system for use with its BK Flex Focus ultrasound systems, for assistance during precise, targeted prostate biopsies, in Austria, Belgium, Denmark, Germany, Great Britain, Luxemburg, North America, Sweden Switzerland and The Netherlands.

The BioJet Fusion system overlays real-time ultrasound images from the BK Flex Focus ultrasound system with MRI identified lesions to provide real-time guidance during prostate biopsies. Analogic's European launch of this advanced technology for MRI/ultrasound fusion guided biopsies took place at the 29th Annual European Association of Urology (EAU) Congress in Stockholm, Sweden, April 11-15.

The combination of the Flex Focus and BioJet offers a complete system that will support both transperineal and transrectal biopsy methods. The BK endocavity biplane transducer (8848) is ideal for transperineal fusion biopsies. In addition, there are two options for transrectal fusion biopsies — the BK triplane (8818) and BK biplane transducer (8808e). Data is easily imported and exported allowing for a more convenient working process between urologists and radiologists.

Comprehensive biopsy reports contain fused MRI and ultrasound images, and biopsy cores. The complete system is simple to use with an intuitive user interface that includes easy contouring and fine-tuning, designed specifically for busy urology practices. Finally, the Flex Focus with the BioJet system has a small footprint, enabling it to fit into tight spaces in a clinic or practice.

For more information: www.analogicultrasound.com/fusion


Related Content

News | Radiation Oncology

July 10, 2026 — A new study led by researchers at the Icahn School of Medicine at Mount Sinai found that although the ...

Time July 10, 2026
arrow
News | Radiation Oncology

July 8, 2026 — GE HealthCare and Mayo Clinic have announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy ...

Time July 09, 2026
arrow
News

May 21, 2026 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 22, 2026
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

In a new 3-part video series on advancements in diagnostic radiology with Robert L. Bard, MD, PC, DABR, FASLMS ...

Time April 10, 2024
arrow
News | Artificial Intelligence

March 21, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time March 21, 2024
arrow
Subscribe Now